4D Molecular Therapeutics (FDMT) Total Current Liabilities (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Total Current Liabilities data on file, last reported at $43.4 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 61.36% year-over-year to $43.4 million in Q1 2026; TTM through Mar 2026 was $43.4 million, a 61.36% increase from a year earlier, with the FY2025 full-year figure at $44.0 million, up 50.9% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $43.4 million, down from $44.0 million in the prior quarter.
• Over the last five years, Total Current Liabilities for FDMT reached as high as $44.0 million in Q4 2025 and fell as low as $11.3 million in Q1 2023.
• Historically, Total Current Liabilities has averaged $23.4 million across 5 years, with a median of $19.0 million in 2023.
• Across the five-year window, Total Current Liabilities retreated 13.11% in 2022 and soared 78.72% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $15.7 million in 2022, then grew by 20.47% to $19.0 million in 2023, then surged by 53.81% to $29.1 million in 2024, then surged by 50.9% to $44.0 million in 2025, then decreased by 1.32% to $43.4 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $43.4 million in Q1 2026, $44.0 million in Q4 2025, and $37.1 million in Q3 2025.